360iResearch Logo
Global Antidiabetic Drug Market
Report Code: MRR-6AA367B | Publishing Date: May 2020 | Number of Pages: 209
Global Antidiabetic Drug Market | Market Research Report | Cumulative Impact of COVID-19

Market Dynamics:

The factors attributing to the growth of the market are strong product pipeline of antidiabetics, increasing consumer awareness level and improved technology, changing lifestyle of people and irregular dietary habits, and globally rising prevalence of diabetes and increasing obesity among people. However, some factors such as prohibitive cost of insulin may hinder the market growth. The Antidiabetic Drug Market is expected to showcase the opportunities such as governments and private companies to work together for the supply of inexpensive drugs, ongoing research and development, and advancement in the healthcare and pharmaceutical sectors. In the near future market may face the possible challenges in the growth due to wide availability of antidiabetics drugs. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the Antidiabetic Drug Market.

Market Segmentation & Coverage:

The research report categorizes the Antidiabetic Drug Market to forecast the revenues and analyze the trends in each of the following segments:

On the basis of Disease, the Antidiabetic Drug Market is studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.

On the basis of Patient, the Antidiabetic Drug Market is studied across Adult, Geriatric, and Pediatric.

On the basis of Type, the Antidiabetic Drug Market is studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.

On the basis of Geography, the Antidiabetic Drug Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The Antidiabetic Drug Market is highly competitive and characterized by the presence of a large number of international and regional players in the market. The market has witnessed increasing competition between vendors based on the pricing model, technology differentiation, brand name, quality of service, price differentiation, and technical expertise.

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drug Market including AstraZeneca plc, Biocon Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Halozyme Therapeutics, Inc., Johnson & Johnson, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., sanofi-aventis U.S. LLC, Takeda Pharmaceutical Company Ltd, Tonghua Dongbao Pharmaceutical Co., Ltd., and Wockhardt Limited.

Scope of the Report:

AttributeDetails
Base Year for Estimation2019
Historical Period2017 - 2018
Estimation Period2020 - 2021
Forecast Year2025
Market RepresentationRevenue in USD Million
Report CoverageRevenue Forecast, Company Share, Competitive Landscape, and Industry Trends.
Customization ScopeIf you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization. We offer 20% free customization which is equivalent to 5 analysts working days.

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of the Antidiabetic Drug Market. Moreover, the study highlights current market trends and provides forecast. We also have highlighted future trends in the Antidiabetic Drug Market that will impact the demand during the forecast period. Moreover, the competitive analysis of the Antidiabetic Drug Market brings an insight on the company usability profiles of the leading players. Additionally, the analysis highlights business overview, strategy, and SWOT analysis of the key companies in the market.

Reasons to Buy:

The Antidiabetic Drug Market research study reveals hidden insights and dynamic, which in turn helps the players in the ecosystem take better strategic decisions. The firms looking for purchasing the Antidiabetic Drug Market research report could look for following prospects on their way to better understand the market that can aid further decision making and possibly identify the best opportunities to exploit.

  • Evaluate the qualitative and quantitative aspects of the report and analyze the Antidiabetic Drug Market penetration with respect to industries and geographies.
  • Evaluates the key vendors and deeply analyze competitive landscape, revenue pockets, market trends, growth prospects, pain points, drivers, restraints, challenges and opportunities of the Antidiabetic Drug Market.
  • Evaluate the key vendors in the Antidiabetic Drug Market in terms of products satisfaction and business strategy. This helps identify consumer preferences and understand its current position in 360iResearch FPNV Positioning Matrix.
  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & Coverage
    3. Years Considered for the Study
    4. Currency & Pricing
    5. Language
    6. Stakeholders
  2. Research Methodology
    1. Research Process
      1. Define: Research Objective
      2. Determine: Research Design
      3. Prepare: Research Instrument
      4. Collect: Data Source
      5. Analyze: Data Interpretation
      6. Formulate: Data Verification
      7. Publish: Research Report
    2. Research Execution
      1. Initiation: Research Process
      2. Planning: Develop Research Plan
      3. Execution: Conduct Research
      4. Verification: Finding & Analysis
      5. Publication: Research Report
    3. Research Outcome
      1. 360iResearch Market Share Analysis
      2. 360iResearch Competitive Strategic Window
  3. Executive Summary
    1. Market Outlook
    2. Disease Outlook
    3. Patient Outlook
    4. Type Outlook
    5. Geography Outlook
    6. Competitor Outlook
  4. Market Overview
    1. Introduction
    2. Antidiabetic Drug Market, By Geography
  5. Market Dynamics
    1. Introduction
      1. Drivers
        1. Changing lifestyle of people and irregular dietary habits
        2. Strong product pipeline of antidiabetics
        3. Globally rising prevalence of diabetes and increasing obesity among people
        4. Increasing consumer awareness level and improved technology
      2. Restraints
        1. Prohibitive cost of Insulin
      3. Opportunities
        1. Advancement in the healthcare and pharmaceutical sectors
        2. Ongoing research and development
        3. Governments and private companies to work together for the supply of inexpensive drugs
      4. Challenges
        1. Wide availability of antidiabetics drugs
  6. Market Insights
    1. Porters Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    2. Cumulative Impact of COVID-19
    3. Client Customizations
  7. Global Antidiabetic Drug Market, By Disease
    1. Introduction
    2. Diabetes Mellitus Type 1
    3. Diabetes Mellitus Type 2
  8. Global Antidiabetic Drug Market, By Patient
    1. Introduction
    2. Adult
    3. Geriatric
    4. Pediatric
  9. Global Antidiabetic Drug Market, By Type
    1. Introduction
    2. Alpha-glucosidase Inhibitors
    3. Biguanides
    4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
    5. GLP-1 (Glucagon-like Peptide) Agonists
    6. Insulin
      1. Intermediate-acting Insulin
      2. Long-acting Analog
      3. Premixed Insulin
      4. Rapid-acting Analog
      5. Short-acting Analog
    7. Meglitinides
    8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
    9. Sulphonylureas
    10. Thiazolidinedione
  10. Americas Antidiabetic Drug Market
    1. Introduction
    2. Argentina
    3. Brazil
    4. Canada
    5. Mexico
    6. United States
  11. Asia-Pacific Antidiabetic Drug Market
    1. Introduction
    2. Australia
    3. China
    4. India
    5. Indonesia
    6. Japan
    7. Malaysia
    8. Philippines
    9. South Korea
    10. Thailand
  12. Europe, Middle East & Africa Antidiabetic Drug Market
    1. Introduction
    2. France
    3. Germany
    4. Italy
    5. Netherlands
    6. Qatar
    7. Russia
    8. Saudi Arabia
    9. South Africa
    10. Spain
    11. United Arab Emirates
    12. United Kingdom
  13. Competitive Landscape
    1. 360iResearch FPNV Positioning Matrix
      1. Quadrants
      2. Business Strategy
      3. Product Satisfaction
    2. 360iResearch Market Ranking Analysis
    3. 360iResearch Market Share Analysis
    4. Competitive Scenario
      1. Merger & Acquisition
      2. Agreement, Collaboration & Partnership
      3. New Product Launch & Enhancement
      4. Investment & Funding
  14. Company Usability Profiles
    1. AstraZeneca plc
    2. Biocon Limited
    3. Boehringer Ingelheim GmbH
    4. Bristol-Myers Squibb Company
    5. Eli Lilly and Company
    6. Halozyme Therapeutics, Inc.
    7. Johnson & Johnson
    8. Merck KGaA
    9. Novo Nordisk A/S
    10. Oramed Pharmaceuticals Inc.
    11. Pfizer Inc.
    12. sanofi-aventis U.S. LLC
    13. Takeda Pharmaceutical Company Ltd
    14. Tonghua Dongbao Pharmaceutical Co., Ltd.
    15. Wockhardt Limited
  15. Appendix
    1. Discussion Guide
    2. Edition Details
    3. License Details
    4. Pricing Details

List of Tables

  1. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2017-2025 (USD MILLION)
  2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  25. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  26. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  27. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  28. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  29. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  30. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  31. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  32. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  33. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  34. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  35. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  36. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  37. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  38. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  39. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  40. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  41. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  42. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  43. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  44. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  45. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  46. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  47. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  48. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  49. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  50. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  51. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  52. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  53. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  54. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  56. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  57. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  58. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  59. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  60. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  61. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  62. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  63. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  64. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  65. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  66. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  67. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  68. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  69. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  70. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  71. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  72. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  73. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  74. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  75. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017-2025 (USD MILLION)
  76. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  77. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  78. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  79. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  80. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  81. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  82. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  83. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  84. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  85. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  86. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  87. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  88. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  89. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  90. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  91. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  92. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  93. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  94. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  95. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  96. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  97. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  98. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  99. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  100. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  101. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  102. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  103. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  104. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  105. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  106. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  107. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  108. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  109. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2017-2025 (USD MILLION)
  110. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017-2025 (USD MILLION)
  111. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017-2025 (USD MILLION)
  112. GLOBAL ANTIDIABETIC DRUG MARKET: SCORES
  113. GLOBAL ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
  114. GLOBAL ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
  115. GLOBAL ANTIDIABETIC DRUG MARKET: RANKING
  116. GLOBAL ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
  117. GLOBAL ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION & PARTNERSHIP
  118. GLOBAL ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  119. GLOBAL ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
  120. GLOBAL ANTIDIABETIC DRUG MARKET: EDITION DETAILS
  121. GLOBAL ANTIDIABETIC DRUG MARKET: LICENSE DETAILS
  122. GLOBAL ANTIDIABETIC DRUG MARKET: PRICING DETAILS

List of Figures

  1. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH PROCESS
  2. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH EXECUTION
  3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2019 VS 2025 (USD MILLION)
  4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2019 VS 2025 (USD MILLION)
  5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2019 VS 2025 (USD MILLION)
  6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
  7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  8. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE
  9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2017-2025 (USD MILLION)
  10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2019 VS 2025 (USD MILLION)
  11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  12. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
  13. GLOBAL ANTIDIABETIC DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
  14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2019 VS 2025 (USD MILLION)
  15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2025 (USD MILLION)
  16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2019 VS 2025 (USD MILLION)
  17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2025 (USD MILLION)
  18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
  19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2025 (USD MILLION)
  20. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  21. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  22. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025 (USD MILLION)
  23. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
  1. AstraZeneca plc
  2. Biocon Limited
  3. Boehringer Ingelheim GmbH
  4. Bristol-Myers Squibb Company
  5. Eli Lilly and Company
  6. Halozyme Therapeutics, Inc.
  7. Johnson & Johnson
  8. Merck KGaA
  9. Novo Nordisk A/S
  10. Oramed Pharmaceuticals Inc.
  11. Pfizer Inc.
  12. sanofi-aventis U.S. LLC
  13. Takeda Pharmaceutical Company Ltd
  14. Tonghua Dongbao Pharmaceutical Co., Ltd.
  15. Wockhardt Limited